The Hong Kong Stock Exchange’s revolutionary change to its listing regime for biotechnology companies is starting to pay off, as the pipeline of pre-revenue firms looking to go public builds. But there are numerous challenges ahead, not least in understanding the sector and the risks involved. Jonathan Breen reports.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.